Dr. Lanzkowsky noted, "As the use of breast MRI increases so does the number of false positive biopsies. Methods to reduce the number of false positive biopsies are needed. Breast-Specific Gamma Imaging can corroborate a benign second look ultrasound, mitigate the need for continued short interval follow-up MRI studies, or confirm the need for a biopsy. Early indicators suggest that the use of BSGI can decrease the false positive biopsy rates resulting from breast MRI."
About Dilon Technologies, Inc.
Dilon Technologies is bringing innovative new medical products to the market based on research conducted at leading national research laboratories. Dilon's cornerstone product is the Dilon 6800 Gamma Camera -- a high-resolution, compact gamma camera, now being used to perform Breast-Specific Gamma Imaging (BSGI), a molecular imaging technique that images the metabolic activity of breast lesions through radiotracer uptake, and other general nuclear medicine imaging. Several leading medical centers around the country are now offering BSGI to their patients, including: Beth Israel Medical Center, New York; George Washington University Medical Center, Washington, D.C.; Alexian Brothers Medical Center, Chicago; Methodist Hospital, Philadelphia; and West Valley Imaging, Las Vegas.
To find out more about BSGI or the Dilon 6800 Gamma Camera please visit http://www.dilon.com
| SOURCE Dilon Technologies, Inc. Copyright©2008 PR Newswire. All rights reserved |